A study to find out whether clozapine results in development of metabolic syndrome in Schizophrenia patients
Not Applicable
- Conditions
- Health Condition 1: F209- Schizophrenia, unspecified
- Registration Number
- CTRI/2024/07/070464
- Lead Sponsor
- AIIMS Raipur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All genders aged between 18 years to 65 years.
2. All patients with Schizophrenia diagnosed as per International Classification of disease 10 (ICD-10).
3. Patients prescribed Clozapine.
4. Medically stable patients.
Exclusion Criteria
1. Unstable patients i.e. patients with violence, suicide risk, and risk of harm to self/others.
2. Patients with diagnosable intellectual disability.
3. Pregnant or lactating patients.
4. Medically unstable patients.
5. Severely physical disability or locomotive disability.
6. History of substance dependence other than tea or coffee.
7. History of significant weight loss in the past month.
8. Patients on metabolism-friendly medication (Such as Aripiprazole, Brexpiprazole, Lurasidone, Topiramate etc).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method